Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome

Blood

Volumn 90, Issue 9, 1997, Pages 3364-3369

  List, Alan F ^a   Brasfield, Farah ^b   Heaton, Ruth ^b   Glinsmann Gibson, Betty ^b   Crook, Linda ^b   Taetle, Raymond ^b   Capizzi, Robert ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE;

ADULT; AGED; ARTICLE; BURST FORMING UNIT E; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT GEMM; COLONY FORMING UNIT GM; FATIGUE; FEMALE; HEMATOPOIESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYELODYSPLASTIC SYNDROME; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REFRACTORY ANEMIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0030735082     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.9.3364     Document Type: Article

References (23)

1. List AF, Garewal HS, Sandberg AA: The myelodysplastic syndromes: Biology and implications for management [review]. J Clin Oncol 8:1424, 1990
2. Merchav S, Wagemaker G, Souza LM, Tatarsky I: Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors. Leukemia 5:340, 1991
3. Hoefsloot LH, Vanamelsvoort MP, Breeders LCAM, Vanderplas DC, Vanlom K, Hoogerbrugge H, Touw IP, Lowenberg B: Erythropoietin-induced activation of STATS is impaired in the myelodysplastic syndrome. Blood 89:1690, 1997
4. Raza A, Gezer S, Mundle S, Gao X-Z, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H: Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86:268, 1995
5. Greenberg PL: Treatment of myelodysplastic syndromes with hemopoietic growth factors [review]. Semin Oncol 19:106, 1992
6. Schuster MW, Larson RA, Thompson JA, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) for myelodysplastic syndrome (MDS): Results of a multicenter randomized controlled trial. Blood 76:18a, 1990 (abstr, suppl 1)
7. Stebler C, Tichelli A, Dazzi H, Gratwohl A, Nissen C, Speck B: High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: A pilot study. Exp Hematol 18:1204, 1990
8. Bowen D, Culligan D, Jacobs A: The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol 77:419, 1991
9. van Kamp H, Prinsze-Postema TC, Kluin PM, den Ottolander GJ, Willemze R, Fibbe WE: Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. Br J Haematol 78:488, 1991
10. Ganser A, Seipelt G, Lindemann A, Ottmann OG, Falk S, Eder M, Becher R, Hoffken K, Buchner T, et al: Effects of recombi- nant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76:455, 1990
11. List AF, Hersh EM, Taetle R, Rinehart J, Quick D, Neidhart JA: Phase I/II trial of subcutaneous recombinant interleukin-3 in patients with bone marrow failure. Proc Am Assoc Cancer Res 33:243a, 1992 (abstr)
12. Hellstrom-Lindberg E, Birgegard G, Carlsson M, Carneskog J, Dahl IM, Grimfors G, Merk K, Tangen JM, Winqvist I, et al: A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 11:221, 1993
13. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg PL: Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin; Evidence for in vivo synergy. Blood 87:4076, 1996
14. Glover D, Glick JH, Weiler C, Hurowitz S, Kligerman MM: WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial. J Clin Oncol 4:584, 1986
15. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101, 1996
16. List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL: Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol 23:58, 1996
17. Anonymous: Amifostine Investigator's Manual. US Bioscience, 1996 (unpub)
18. List AF, Heaton R, Glinsmann-Gibson B, Capizzi R: Amifostine stimulates formation of multipotent progenitors and generates macroscopic colonies in normal and myelodysplastic bone marrow. Proc Am Soc Clin Oncol 15:449, 1996 (abstr)
19. Ash RC, Detrick DA, Zanjani ED: Studies of human pluripotential hemopoietic stem cells (CFU-GEMM) in vitro. Blood 58:309, 1981
20. Knight GD, Laubscher KH, Fore ML, Clark DA, Scallen TJ: Vitalethine modulates erythropoiesis and neoplasia. Cancer Res 54:5623, 1994
21. Kibbelaar RE, van Kamp H, Dreef EJ, de Groot-Swings G, Kluin-Nelemans J, Beverstock GC, Fibbe WE, Kluin PM: Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes. Blood 79:1823, 1992
22. Kroef MJ, Fibbe WE, Mout R, Jansen RP, Haak HL, Wessels JW, Van Kamp H, Willemze R, Landegent JE: Myeloid but not lymphoid cells carry the 5q deletion: Polymerase chain reaction analysis of loss of heterozygosity using mini-repeat sequences on highly purified cell fractions. Blood 81:1849, 1993
23. Bernell P, Jacobsson B, Nordgren A, Hast R: Clonal cell lineage involvement in myelodysplastic syndromes studied by fluorescence in situ hybridization and morphology. Leukemia 10:662, 1996